Quick Answer
Guardant Health, Inc. reported Total Revenue of $982.02 million for fiscal year 2025.
Guardant Health, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $982.02M +32.9% |
$739.02M +31.0% |
$563.95M +25.5% |
$449.54M +20.3% |
$373.65M +30.3% |
$286.73M +33.8% |
| Net Income | -$416.28M +4.6% |
-$436.37M +9.0% |
-$479.45M +26.8% |
-$654.59M -70.1% |
-$384.77M | — |
| Diluted EPS | -$3.32 +6.7% |
-$3.56 +16.8% |
-$4.28 +33.2% |
-$6.41 -60.2% |
-$4.00 -53.8% |
-$2.60 -209.5% |
| Total Assets | $2.01B +35.5% |
$1.49B -16.8% |
$1.79B +11.0% |
$1.61B -27.0% |
$2.20B -3.0% |
$2.27B +136.0% |
| Cash and Equivalents | $378.20M -28.0% |
$525.54M -53.6% |
$1.13B +700.3% |
$141.65M -71.2% |
$492.20M -40.9% |
$832.98M +481.6% |
| Stockholders Equity | -$99.31M +28.9% |
-$139.65M -188.0% |
$158.68M +163.7% |
$60.18M -90.7% |
$645.00M -50.3% |
$1.30B +62.6% |
| R&D Expense | $364.19M +4.7% |
$347.75M -5.3% |
$367.19M -1.8% |
$373.81M +42.0% |
$263.22M +75.6% |
$149.86M +73.7% |
| Operating Income | -$437.25M +1.4% |
-$443.59M +21.4% |
-$564.73M -3.7% |
-$544.38M -32.5% |
-$411.00M -61.2% |
-$254.95M -209.5% |
| Shares Outstanding | 130.64M +5.4% |
123.99M +1.9% |
121.63M +18.5% |
102.62M +0.8% |
101.77M +1.6% |
100.21M +6.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $265.20M | +38.5% | +14.3% |
| Net Income | September 30, 2025 | -$92.72M | +13.9% | +7.2% |
| Diluted EPS | September 30, 2025 | -$0.74 | +15.9% | +7.5% |
| Total Assets | September 30, 2025 | $1.28B | -17.0% | -4.1% |
| Cash and Equivalents | September 30, 2025 | $580.01M | -0.9% | -7.8% |
| Stockholders Equity | September 30, 2025 | -$354.47M | -489.8% | -16.0% |
| R&D Expense | September 30, 2025 | $89.96M | +3.0% | +2.9% |
| Operating Income | September 30, 2025 | -$98.99M | +15.6% | +7.0% |
| Shares Outstanding | September 30, 2025 | 125.01M | +1.5% | +0.4% |
- Guardant Health, Inc. reported Total Revenue of $982.02 million for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +32.9% in Total Revenue compared to the prior fiscal year.
- Guardant Health, Inc. reported Net Income of -$416.28 million for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +4.6% in Net Income compared to the prior fiscal year.
- Guardant Health, Inc. reported Diluted EPS of $3.32 per share (loss) for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +6.7% in Diluted EPS compared to the prior fiscal year.
- Guardant Health, Inc. reported Total Assets of $2.01 billion for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +35.5% in Total Assets compared to the prior fiscal year.
- Guardant Health, Inc. reported Cash and Equivalents of $378.20 million for fiscal year 2025.
- Guardant Health, Inc. showed a decrease of -28.0% in Cash and Equivalents compared to the prior fiscal year.
- Guardant Health, Inc. reported Stockholders Equity of -$99.31 million for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +28.9% in Stockholders Equity compared to the prior fiscal year.
- Guardant Health, Inc. reported R&D Expense of $364.19 million for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +4.7% in R&D Expense compared to the prior fiscal year.
- Guardant Health, Inc. reported Operating Income of -$437.25 million for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +1.4% in Operating Income compared to the prior fiscal year.
- Guardant Health, Inc. reported Shares Outstanding of 130.64 million shares for fiscal year 2025.
- Guardant Health, Inc. showed an increase of +5.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: